FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2009. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3653858012 | Technetium (99m-Tc) fanolesomab (substance) | en | Fully specified name | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 3653859016 | Technetium (99m-Tc) fanolesomab | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Technetium (99m-Tc) fanolesomab (substance) | Is a | Technetium-99m (substance) | false | Inferred relationship | Some | ||
| Technetium (99m-Tc) fanolesomab (substance) | Is a | Technetium radioisotope | true | Inferred relationship | Some | ||
| Technetium (99m-Tc) fanolesomab (substance) | This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. | Technetium-99m (substance) | true | Inferred relationship | Some | ||
| Technetium (99m-Tc) fanolesomab (substance) | Is a | allergène médicamenteux | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Technetium[99mTc] fanolesomab injection | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | False | Technetium (99m-Tc) fanolesomab (substance) | Inferred relationship | Some | |
| Product containing technetium (99m-Tc) fanolesomab in parenteral dose form (medicinal product form) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | True | Technetium (99m-Tc) fanolesomab (substance) | Inferred relationship | Some | 1 |
This concept is not in any reference sets